Veeva Systems Inc. (NYSE:VEEV) Shares Bought by Harrington Investments INC

Harrington Investments INC grew its holdings in Veeva Systems Inc. (NYSE:VEEV) by 1.2% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 6,710 shares of the technology company’s stock after acquiring an additional 79 shares during the quarter. Harrington Investments INC’s holdings in Veeva Systems were worth $1,411,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in VEEV. Postrock Partners LLC purchased a new position in Veeva Systems in the 4th quarter valued at $2,201,000. Skandinaviska Enskilda Banken AB publ boosted its holdings in shares of Veeva Systems by 14.1% in the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 236,757 shares of the technology company’s stock valued at $50,067,000 after acquiring an additional 29,338 shares in the last quarter. ANTIPODES PARTNERS Ltd increased its stake in shares of Veeva Systems by 115.1% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,198 shares of the technology company’s stock worth $252,000 after acquiring an additional 641 shares during the period. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Veeva Systems during the fourth quarter worth about $292,000. Finally, Farther Finance Advisors LLC boosted its position in Veeva Systems by 4.3% during the fourth quarter. Farther Finance Advisors LLC now owns 3,355 shares of the technology company’s stock worth $705,000 after purchasing an additional 139 shares in the last quarter. Hedge funds and other institutional investors own 88.20% of the company’s stock.

Veeva Systems Price Performance

Shares of VEEV opened at $233.84 on Friday. Veeva Systems Inc. has a 12 month low of $170.25 and a 12 month high of $258.93. The stock has a market cap of $37.96 billion, a PE ratio of 57.74, a P/E/G ratio of 1.89 and a beta of 0.88. The stock’s 50-day moving average is $227.12 and its two-hundred day moving average is $221.25.

Analyst Ratings Changes

Several analysts have recently commented on VEEV shares. Royal Bank of Canada increased their price target on shares of Veeva Systems from $275.00 to $285.00 and gave the company an “outperform” rating in a research report on Friday, December 6th. Truist Financial upped their price objective on Veeva Systems from $210.00 to $217.00 and gave the company a “hold” rating in a research report on Thursday, March 6th. Barclays lifted their price objective on Veeva Systems from $260.00 to $275.00 and gave the stock an “overweight” rating in a research report on Friday, December 6th. Piper Sandler raised their price target on shares of Veeva Systems from $280.00 to $290.00 and gave the stock an “overweight” rating in a research note on Friday, December 6th. Finally, KeyCorp cut their price objective on shares of Veeva Systems from $285.00 to $255.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $255.28.

Veeva Systems Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.